FibroGen, Inc. (FGEN)

FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of $31.67 million. The enterprise value is $71.36 million.

Market Cap	31.67M
Enterprise Value	71.36M

Important Dates

The last earnings date was Monday, March 17, 2025, after market close.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroGen has 100.92 million shares outstanding. The number of shares has increased by 2.82% in one year.

Current Share Class	100.92M
Shares Outstanding	100.92M
Shares Change (YoY)	+2.82%
Shares Change (QoQ)	+0.31%
Owned by Insiders (%)	1.53%
Owned by Institutions (%)	29.24%
Float	92.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.06
Forward PS	0.21
PB Ratio	-0.17
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.41
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.47

Current Ratio	1.47
Quick Ratio	0.60
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.88

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-25.66%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-161.25%
Revenue Per Employee	$131,649
Profits Per Employee	-$211,462
Employee Count	225
Asset Turnover	0.09
Inventory Turnover	10.95

Taxes

Income Tax	-269,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.84% in the last 52 weeks. The beta is 0.83, so FibroGen's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-87.84%
50-Day Moving Average	0.46
200-Day Moving Average	0.53
Relative Strength Index (RSI)	38.62
Average Volume (20 Days)	1,660,287

Short Selling Information

The latest short interest is 2.95 million, so 2.92% of the outstanding shares have been sold short.

Short Interest	2.95M
Short Previous Month	2.91M
Short % of Shares Out	2.92%
Short % of Float	3.18%
Short Ratio (days to cover)	0.61

Income Statement

In the last 12 months, FibroGen had revenue of $29.62 million and -$47.58 million in losses. Loss per share was -$0.48.

Revenue	29.62M
Gross Profit	-81.63M
Operating Income	-130.96M
Pretax Income	-168.39M
Net Income	-47.58M
EBITDA	-128.27M
EBIT	-130.96M
Loss Per Share	-$0.48

Balance Sheet

The company has $50.48 million in cash and $90.17 million in debt, giving a net cash position of -$39.69 million or -$0.39 per share.

Cash & Cash Equivalents	50.48M
Total Debt	90.17M
Net Cash	-39.69M
Net Cash Per Share	-$0.39
Equity (Book Value)	-183.64M
Book Value Per Share	-2.24
Working Capital	63.20M

Cash Flow

In the last 12 months, operating cash flow was -$138.00 million and capital expenditures -$266,000, giving a free cash flow of -$138.27 million.

Operating Cash Flow	-138.00M
Capital Expenditures	-266,000
Free Cash Flow	-138.27M
FCF Per Share	-$1.37

Margins

Gross margin is -275.59%, with operating and profit margins of -442.13% and -160.63%.

Gross Margin	-275.59%
Operating Margin	-442.13%
Pretax Margin	-517.76%
Profit Margin	-160.63%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.82%
Shareholder Yield	-2.82%
Earnings Yield	-150.24%
FCF Yield	-436.61%

Analyst Forecast

The average price target for FibroGen is $10.00, which is 3,086.74% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	3,086.74%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FibroGen has an Altman Z-Score of -13.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.71
Piotroski F-Score	2